Vanderbilt University Medical Center | Vanderbilt - Ingram Cancer Center

Research site

(Unclaimed)

Location

3322 West End Avenue Suite 1000, Nashville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Teclistamab

Pembrolizumab

Daratumumab

Dexamethasone

Luspatercept

Domvanalimab

Amivantamab

Vincristine

Cyclophosphamide

Vinorelbine

Parent organization

This site is a part of Vanderbilt University Medical Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 11 total trials

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Domvanalimab

Drug: Zimberelimab

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers

Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Astex-...

Invitation-only

Myelodysplastic Syndromes

Acute Myeloid Leukemia

Drug: ASTX727

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of a...

Enrolling

Advanced or Metastatic Colorectal Cancer

Biological: Leucovorin

Biological: Fluorouracil

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and t...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Daratumumab

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the...

Enrolling

Relapsed/ Refractory Multiple Myeloma

Drug: PD-1 Inhibitor

Drug: Talquetamab

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with p...

Active, not recruiting

Multiple Myeloma

Drug: Dexamethasone

Drug: Teclistamab

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:* Participants rec...

Enrolling

Beta-thalassemia

Myelodysplastic Syndromes (MDS)

Drug: Luspatercept

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carci...

Active, not recruiting

Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

Drug: Cisplatin/Carboplatin; 5FU

Drug: pembrolizumab